Quince Therapeutics (QNCX) Total Current Liabilities (2018 - 2026)

Quince Therapeutics has reported Total Current Liabilities for 9 years, with the latest figure at $8.5 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 13.83% year-over-year to $8.5 million in Q2 2026; TTM through Jun 2026 was $8.5 million, a 13.83% increase from a year earlier, with the FY2025 full-year figure at $43.2 million, up 493.93% from the prior year.
• Total Current Liabilities was $8.5 million for Q2 2026 at Quince Therapeutics, down from $8.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $43.2 million in Q4 2025, with the low at $2.0 million in Q2 2023.
• Average Total Current Liabilities over 5 years is $9.8 million, with a median of $7.9 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities tumbled 78.42% in 2022, then soared 493.93% in 2025.
• Over 5 years, Total Current Liabilities stood at $3.1 million in 2022, then surged by 211.89% to $9.6 million in 2023, then fell by 23.97% to $7.3 million in 2024, then jumped by 493.93% to $43.2 million in 2025, then slumped by 80.34% to $8.5 million in 2026.
• The last three Total Current Liabilities figures came in at $8.5 million (Q2 2026), $8.8 million (Q1 2026), and $43.2 million (Q4 2025), per Business Quant data.